MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
MANNKIND CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.09+0.05 (+1.64%)
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
56.7%
182M of 322M shares
Institutional holders
259
52 new, 39 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
1 buys · 14 sales
Net sold $3.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 22,297,032 | 8.30% | 13G (passive) amendment | Dec 31, 2023 |
| State Street Corporation | 18,683,483 | 6.10% | 13G (passive) | Mar 31, 2026 |
| Rubric Capital Management LP | 18,000,000 | 5.83% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 15,450,421 | 5.00% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MNKD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 32,133,223 | 9.99% | $136.89M | +3,532,225 | 0.00% |
| Rubric Capital Management LP | 18,000,000 | 5.60% | $76.68M | +14,379,587 | 0.70% |
| State Street Corp | 16,174,043 | 5.03% | $68.90M | −2,509,440 | 0.00% |
| Vanguard Capital Management LLC | 13,169,392 | 4.10% | $56.10M | +278,326 | 0.00% |
| Geode Capital Management, LLC | 7,947,203 | 2.47% | $33.86M | +442,056 | 0.00% |
| Wellington Management Group Llp | 7,844,807 | 2.44% | $33.42M | +4,561,628 | 0.01% |
| Frazier Life Sciences Management, L.P. | 6,600,000 | 2.05% | $28.12M | +700,000 | 0.61% |
| Deep Track Capital, LP | 6,000,000 | 1.87% | $25.56M | New | 0.37% |
| 180 Wealth Advisors, LLC | 4,959,351 | 1.54% | $21.13M | +667,648 | 2.12% |
| FMR LLC | 4,101,046 | 1.28% | $17.47M | +620,082 | 0.00% |
| TSP Capital Management Group, LLC | 3,972,675 | 1.24% | $16.92M | New | 4.05% |
| Aqr Capital Management LLC | 3,808,824 | 1.18% | $16.23M | +3,355,838 | 0.01% |
| Morgan Stanley | 3,474,870 | 1.08% | $14.80M | −2,318,277 | 0.00% |
| Braidwell LP | 3,458,429 | 1.08% | $14.73M | New | 0.54% |
| Vanguard Portfolio Management LLC | 3,002,169 | 0.93% | $12.79M | −169,655 | 0.00% |
| Northern Trust Corp | 2,887,290 | 0.90% | $12.30M | +211,340 | 0.00% |
| UBS Group AG | 2,886,231 | 0.90% | $12.30M | −5,369,199 | 0.00% |
| Two Sigma Investments, LP | 2,693,712 | 0.84% | $11.48M | −202,162 | 0.01% |
| Charles Schwab Investment Management Inc | 2,598,727 | 0.81% | $11.07M | +49,660 | 0.00% |
| Bank Of America Corp /De/ | 2,364,872 | 0.74% | $10.07M | −1,018,805 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 259 | 182M | 56.7% | 52 / 96 | 62 / 39 | 51M | 46M |
| Q1 2026 | 250 | 177M | 55.0% | 45 / 84 | 71 / 50 | 52M | 35M |
| Q4 2025 | 258 | 178M | 55.4% | 48 / 86 | 69 / 22 | 26M | 23M |
| Q3 2025 | 234 | 175M | 54.4% | 51 / 60 | 75 / 46 | 37M | 30M |
| Q2 2025 | 232 | 168M | 52.3% | 24 / 74 | 71 / 48 | 19M | 27M |
| Q1 2025 | 257 | 177M | 55.1% | 43 / 81 | 71 / 27 | 24M | 13M |
| Q4 2024 | 244 | 168M | 52.3% | 43 / 93 | 50 / 26 | 23M | 8M |
| Q3 2024 | 231 | 155M | 48.1% | 39 / 81 | 52 / 17 | 47M | 8M |
| Q2 2024 | 211 | 138M | 43.0% | 33 / 67 | 62 / 23 | 15M | 17M |
| Q1 2024 | 204 | 140M | 43.5% | 41 / 54 | 55 / 37 | 21M | 16M |
| Q4 2023 | 201 | 135M | 42.0% | 27 / 63 | 49 / 22 | 12M | 15M |
| Q3 2023 | 196 | 139M | 43.2% | 25 / 63 | 53 / 14 | 17M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MNKD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 9,327,332 | 2.90% | $39.73M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 8,517,947 | 2.65% | $36.29M | 0.34% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 7,992,093 | 2.49% | $34.05M | 0.04% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 4,078,401 | 1.27% | $15.38M | 0.29% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 3,526,693 | 1.10% | $15.02M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 3,361,980 | 1.05% | $13.15M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,841,882 | 0.88% | $12.11M | 0.08% | Jun 30, 2026 |
| iShares Biotechnology ETF | 2,077,728 | 0.65% | $8.85M | 0.10% | Jun 30, 2026 |
| Janus Henderson Small/Mid Cap Growth Alpha ETF | 1,678,187 | 0.52% | $6.56M | 0.62% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 1,592,082 | 0.50% | $6.00M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,570,158 | 0.49% | $5.92M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,466,402 | 0.46% | $5.53M | 0.02% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 1,334,950 | 0.42% | $5.03M | 0.10% | May 29, 2026 |
| First Trust Small Cap Growth AlphaDEX Fund | 1,212,660 | 0.38% | $4.74M | 0.37% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 869,782 | 0.27% | $3.28M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer, Director | 2,494,183 | 0.78% | Jul 17, 2026 |
| David Thomson | EVP Genl Counsel & Secretary | 797,554 | 0.25% | Jul 17, 2026 |
| Christopher B. Prentiss | Chief Financial Officer | 318,668 | 0.10% | Jul 17, 2026 |
| Sanjay R. Singh | EVP Technical Operations | 478,966 | 0.15% | Jul 17, 2026 |
| Stuart A. Tross | Chief People & Workpl Officer | 1,123,950 | 0.35% | Jul 17, 2026 |
| Dominic Marasco | Pres, Endocrine Business Unit | 343,398 | 0.11% | Jul 17, 2026 |
| Ajay Ahuja | Chief Medical Officer | 318,200 | 0.10% | Mar 25, 2026 |
| Burkhard Blank | EVP Chief Medical Officer | 460,791 | 0.14% | Jul 17, 2025 |
| Lauren M. Sabella | EVP Operations | 349,841 | 0.11% | Jul 17, 2025 |
| Steven B. Binder | Director | 713,258 | 0.22% | Sep 28, 2026 |
| James Samuel Shannon | Director | 36,458 | 0.01% | May 22, 2026 |
| Christine Mundkur | Director | 27,675 | 0.01% | May 22, 2026 |
| Jennifer Grancio | Director | 110,701 | 0.03% | May 22, 2026 |
| Sabrina Kay | Director | 107,033 | 0.03% | May 22, 2026 |
| Michael A. Friedman | Director | 86,700 | 0.03% | May 22, 2026 |
| Ronald J. Consiglio | Director | 132,342 | 0.04% | May 22, 2026 |
| Anthony C. Hooper | Director | 236,153 | 0.07% | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Steven B. Binder Director | Sep 25, 2026 | Sale(10b5-1 plan) | −39,051 | $3.29 | $128.48K | 713,258 |
| Steven B. Binder Director | Sep 10, 2026 | Sale(10b5-1 plan) | −33,558 | $3.81 | $127.86K | 752,309 |
| Steven B. Binder Director | Aug 7, 2026 | Sale(10b5-1 plan) | −39,051 | $4.06 | $158.55K | 785,867 |
| David Thomson EVP Genl Counsel & Secretary | Jul 17, 2026 | Sale(10b5-1 plan) | −24,109 | $4.05 | $97.64K | 797,554 |
| Steven B. Binder Director | Jul 17, 2026 | Sale(10b5-1 plan) | −52,485 | $4.06 | $213.09K | 824,918 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Option exercise | +93,790 | – | – | 1,123,950 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −33,652 | $4.09 | $137.64K | 1,090,298 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −8,253 | $4.09 | $33.75K | 1,082,045 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −11,572 | $4.09 | $47.33K | 1,070,473 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −12,331 | $4.09 | $50.43K | 1,058,142 |
| Dominic Marasco Pres, Endocrine Business Unit | Jul 15, 2026 | Tax withholding | −3,623 | $4.09 | $14.82K | 343,398 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −63,996 | $4.09 | $261.74K | 2,492,683 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −58,904 | $4.09 | $240.92K | 2,433,779 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −47,481 | $4.09 | $194.20K | 2,556,679 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Option exercise | +350,260 | – | – | 2,796,979 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −192,819 | $4.09 | $788.63K | 2,604,160 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −9,297 | $4.09 | $38.02K | 478,966 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −10,079 | $4.09 | $41.22K | 488,263 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −5,372 | $4.09 | $21.97K | 498,342 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Option exercise | +70,550 | – | – | 525,761 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −22,047 | $4.09 | $90.17K | 503,714 |
| Christopher B. Prentiss Chief Financial Officer | Jul 15, 2026 | Tax withholding | −10,675 | $4.09 | $43.66K | 318,668 |
| Christopher B. Prentiss Chief Financial Officer | Jul 15, 2026 | Tax withholding | −11,572 | $4.09 | $47.33K | 329,343 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Option exercise | +93,790 | – | – | 920,089 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −51,632 | $4.09 | $211.17K | 868,457 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −12,662 | $4.09 | $51.79K | 855,795 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −17,754 | $4.09 | $72.61K | 838,041 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −16,378 | $4.09 | $66.99K | 821,663 |
| Steven B. Binder Director | Jul 15, 2026 | Tax withholding | −4,073 | $4.09 | $16.66K | 882,037 |
| Steven B. Binder Director | Jul 15, 2026 | Tax withholding | −4,634 | $4.09 | $18.95K | 877,403 |
| Steven B. Binder Director | Jul 15, 2026 | Tax withholding | −15,688 | $4.09 | $64.16K | 886,110 |
| Steven B. Binder Director | Jul 15, 2026 | Option exercise | +93,790 | – | – | 901,798 |
| Stuart A. Tross Chief People & Workpl Officer | May 20, 2026 | Award | +33,898 | $2.95 | $100.00K | 1,026,122 |
| Ronald J. Consiglio Director | May 20, 2026 | Award | +10,000 | $2.95 | $29.50K | 132,342 |
| Dominic Marasco Pres, Endocrine Business Unit | May 20, 2026 | Award | +8,474 | $2.95 | $25.00K | 344,246 |
| Steven B. Binder Director | May 12, 2026 | Sale(10b5-1 plan) | −16,940 | $3.29 | $55.73K | 808,008 |
| David Thomson EVP Genl Counsel & Secretary | May 12, 2026 | Sale(10b5-1 plan) | −3,033 | $3.29 | $9.98K | 826,299 |
| Steven B. Binder Director | May 11, 2026 | Tax withholding | −5,560 | $3.52 | $19.57K | 824,948 |
| David Thomson EVP Genl Counsel & Secretary | May 11, 2026 | Tax withholding | −12,387 | $3.52 | $43.60K | 829,332 |
| Michael Castagna Chief Executive Officer, Director | May 11, 2026 | Tax withholding | −34,957 | $3.52 | $123.05K | 2,442,310 |
| Stuart A. Tross Chief People & Workpl Officer | May 11, 2026 | Tax withholding | −8,073 | $3.52 | $28.42K | 992,224 |
| Christopher B. Prentiss Chief Financial Officer | Apr 22, 2026 | Tax withholding | −12,267 | $2.74 | $33.61K | 338,924 |
| Michael Castagna Chief Executive Officer, Director | Mar 10, 2026 | Buy | +100,000 | $2.59 | $259.00K | 2,575,911 |
| James Samuel Shannon Director | Mar 1, 2026 | Award | +12,000 | $3.27 | $39.24K | 64,635 |
| Christopher B. Prentiss Chief Financial Officer | Mar 1, 2026 | Award | +5,000 | $3.27 | $16.35K | 348,854 |
| Anthony C. Hooper Director | Mar 1, 2026 | Award | +35,000 | $3.27 | $114.45K | 236,153 |
| Michael Castagna Chief Executive Officer, Director | Mar 1, 2026 | Award | +15,290 | $3.27 | $50.00K | 2,475,911 |
| Stuart A. Tross Chief People & Workpl Officer | Mar 1, 2026 | Award | +15,290 | $3.27 | $50.00K | 1,000,297 |
| Stuart A. Tross Chief People & Workpl Officer | Jan 8, 2026 | Sale(10b5-1 plan) | −47,006 | $6.33 | $297.55K | 985,007 |
| Michael Castagna Chief Executive Officer, Director | Dec 24, 2025 | Gift | −44,171 | – | – | 2,460,621 |
| Michael Castagna Chief Executive Officer, Director | Dec 17, 2025 | Option exercise | +65,804 | $4.55 | $299.41K | 2,570,596 |
| Michael Castagna Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −65,804 | $6.01 | $395.48K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 16, 2025 | Sale(10b5-1 plan) | −21,310 | $6.00 | $127.86K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 16, 2025 | Option exercise | +21,310 | $4.55 | $96.96K | 2,526,102 |
| Michael Castagna Chief Executive Officer, Director | Dec 12, 2025 | Option exercise | +20,806 | $4.55 | $94.67K | 2,525,598 |
| Michael Castagna Chief Executive Officer, Director | Dec 12, 2025 | Sale(10b5-1 plan) | −20,806 | $6.00 | $124.84K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 2, 2025 | Sale(10b5-1 plan) | −107,920 | $5.57 | $601.11K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 2, 2025 | Option exercise | +107,920 | $4.55 | $491.04K | 2,612,712 |
| David Thomson EVP Genl Counsel & Secretary | Dec 2, 2025 | Option exercise | +60,000 | $4.55 | $273.00K | 901,719 |
| David Thomson EVP Genl Counsel & Secretary | Dec 2, 2025 | Option exercise | +87,780 | $4.60 | $403.79K | 989,499 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Binder Steven Director | Sep 25, 2026 | 39,051 | $128.48K | Sep 25, 2026 | Performance Stock Units |
| Binder Steven Director | Sep 10, 2026 | 33,558 | $132.22K | Sep 10, 2026 | Restricted Stock Units |
| Binder Steven Director | Aug 7, 2026 | 39,051 | $151.91K | Aug 7, 2026 | Performance Stock Units |
| Binder Steven Director | Jul 17, 2026 | 52,485 | $212.04K | Jul 17, 2026 | Restricted Stock Units |
| Thomson David Officer | Jul 17, 2026 | 24,109 | $97.40K | Jul 17, 2026 | Restricted Stock Units |
| David Thomson Officer | May 14, 2026 | 3,033 | $9.89K | May 12, 2026 | Restricted Stock Units |
| Binder Steven Director | May 12, 2026 | 16,940 | $56.92K | May 12, 2026 | Restricted Stock Units |
| Thomson David Officer | May 12, 2026 | 10,113 | $33.98K | May 12, 2026 | Restricted Stock Units |
| A. Tross Stuart Officer | Jan 8, 2026 | 47,000 | $297.51K | Jan 8, 2026 | Performance Shares |
| Castagna Michael Director, Officer | Dec 12, 2025 | 107,920 | $627.02K | Dec 12, 2025 | Exercise of Stock Options |
| Thomson David Officer | Dec 2, 2025 | 147,780 | $802.45K | Dec 2, 2025 | Exercise of Stock Options |
| Castagna Michael Director, Officer | Dec 2, 2025 | 107,920 | $586.01K | Dec 2, 2025 | Exercise of Stock Options |
| Singh Sanjay Officer | Nov 14, 2025 | 18,777 | $94.49K | Nov 14, 2025 | Restricted Stock |
| A. Tross Stuart Officer | Sep 16, 2025 | 47,000 | $250.79K | Sep 16, 2025 | Performance Shares |
| Thomson David Officer | Jul 16, 2025 | 7,466 | $29.43K | Jul 16, 2025 | Restricted Stock |